The Gastritis Treatment Market is anticipated to reach USD 244.23 Million by 2030 at 4.30% CAGR during the forecast period 2022-2030. Gastritis is characterized by a set of conditions that cause inflammation or irritation of the lining of the stomach, for a short or long time. Upper abdominal pain or discomfort is the most common symptom of Gastritis. Gastritis has been broadly categorized into three segments, namely, acute gastritis, chronic gastritis, and erosion of metaplasia or atrophic gastritis. The market for gastritis treatment is expanding worldwide due to drivers such as increasing occurrence of acute and chronic gastritis, advances in the area of medical technologies, increasing fast food chains worldwide, massive adoption of a sedentary lifestyle, and advancement in endoscopy devices that increased the accuracy of diagnosis. Moreover, chronic gastritis patients, rely on acidity reducing medicines for a lifetime, thus fueling the market demand which in turn would boost up the market growth. However, unaffordability and lack of advanced medical device technology in middle-income countries are likely to hamper the gastritis treatment market growth.
Source: World Health Organization, Centers for Disease Control and Prevention, American Heart Association, National Institute of Health, American College of Cardiology, European Heart Network, expert interview, annual report, white paper, company presentation and market research future analysis
The gastritis treatment market is segmented on the basis of diagnosis, treatment type, drug distribution channel, and end-users.
Considering the diagnosis, the market is segmented into blood test, endoscopy, x-ray of the upper digestive system and others.
By treatment type, the gastritis treatment market is segmented into acid-blocking medicines, antibiotics, antacids, and histamine blockers.
With reference to the drug distribution channel, the gastritis treatment market is segmented into retail pharmacy, online pharmacy, and hospital pharmacy.
On account of end-users, the gastritis treatment market is segmented hospitals & clinics and others.
Based on region the market is segmented into Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
The Americas is going to account for the largest share for gastritis treatment market. Drivers such as widespread of fast food chains in this region along with the increasing sedentary life culture which in turn contributes to increasing patient pool of gastritis and rising geriatric population are likely to enhance the growth of gastritis treatment market. Moreover, rising alcohol abuse, the presence of prominent key players is likely to spur the market growth. For instance, According to a published survey, approximately 1 in 100 is a victim of gastritis in the US. Thus, this increasing patient pool will enhance the market growth during the forecasted period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of gastritis treatment market in the American region. Furthermore, according to CMS (Centers for Medicare and Medicaid Services) US health care spending increased 4.3 percent to reach USD 3.3 trillion per person in 2016. Thus, the increasing per capita income of individuals, as well as rising healthcare spending, will aid up the market growth of the Americas.
Europe is the second market leader and holds a healthy share in the gastritis treatment market. The European market is expected to exhibit a sturdy growth rate during the forecast period owing to the availability of advanced treatment facilities, established healthcare infrastructure along with the presence of a flourishing medical device market which helps in efficient and accurate diagnosis. Furthermore, due to the increasing number of lactose-intolerant issues, vulnerability to falling prey of gastritis is more likely to lead to an increasing number of gastritis sufferers. Thus, fueling the market growth during the forecast period.
Asia-Pacific is expected to be the fastest emerging market owing to increasing government initiatives for healthcare reform, increasing adaption of a sedentary lifestyle, and increasing prevalence of gastritis. Moreover, the prevalence of multifocal atrophic gastritis and gastric adenocarcinomas is high in these regions. Furthermore, the presence of renowned domestic pharmaceutical players, as well as the increasing healthcare spending per capita, is going to accelerate the market growth during the forecast period.
The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. With an increasing number of gastrointestinal disorders region in this region, many key players are willing to set up their research and development centers to find a cure for these diseases. Moreover, the government is aiming at improving the healthcare infrastructure. Thus, a steady growth rate might be seen during the forecast period.
Gastritis Treatment Market Share (%), by Region, 2017
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Market Segmentation & Key players
Gastritis Treatment Market, by Diagnosis
Gastritis Treatment Market, by Treatment type
Gastritis Treatment Market, by Drug Distribution Channel
Gastritis Treatment Market, by End-User
Gastritis treatment Market, By Region
Middle East and Africa
|Market Size||2030: Significant Value|
|CAGR||2022-2030: 4.30% CAGR|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment, Drug Distribution, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Abbott Laboratories, AstraZeneca PLC, Novartis AG, Microbiotix, Inc, Reddy’s Laboratories, Lupin Ltd, Perrigo Pharmaceutical, Cipla Inc., Pfizer Inc., SUN Pharmaceuticals Industries limited|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
The Americas is expected to lead the Gastritis Treatment Market.
Rising prevalence of chronic gastritis and advancement in endoscopy devices are adding market growth.
Hospitals and clinics are the end users of gastritis treatment.
Top players in the Gastritis Treatment Market include SUN Pharmaceuticals Industries Limited, Pfizer Inc., Cipla Inc., Perrigo Pharmaceutical, Lupin Ltd, Dr. Reddy’s Laboratories, Microbiotix, Inc, Novartis AG, AstraZeneca PLC, and Abbott Laboratories.
Different strategies used by market players to create a dominance in the Gastritis Treatment Market include acquisitions, product launches, partnerships, and collaborations.